Table 3.

Clinical trials for therapeutics targeting LRRK2.

Clinical trial	Drug name	Drug type	Phase	Funding body
NCT03710707	DNL201	Kinase inhibitor	Phase Ib (completed)	Denali Therapeutics Inc. (South San Francisco, CA, USA)
NCT04056689	BIIB122/DNL151	Kinase inhibitor	Phase Ib (completed)	Denali Therapeutics Inc. (South San Francisco, CA, USA) and Biogen (Cambridge, MA, USA)
NCT05348785	BIIB122/DNL151	Kinase inhibitor	Phase IIb (ongoing)	Denali Therapeutics Inc. (South San Francisco, CA, USA) and Biogen (Cambridge, MA, USA)
NCT05418673	BIIB122/DNL151	Kinase inhibitor	Phase III (ongoing)	Denali Therapeutics Inc. (South San Francisco, CA, USA) and Biogen (Cambridge, MA, USA)
NCT03976349	BIIB094	ASO	Phase I (ongoing)	Biogen (Cambridge, MA, USA)

ASO, antisense oligonucleotides.